» Articles » PMID: 26971015

Dysregulation of MicroRNA Biogenesis in Cancer: the Impact of Mutant P53 on Drosha Complex Activity

Overview
Publisher Biomed Central
Specialty Oncology
Date 2016 Mar 14
PMID 26971015
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

A widespread decrease of mature microRNAs is often observed in human malignancies giving them potential to act as tumor suppressors. Thus, microRNAs may be potential targets for cancer therapy. The global miRNA deregulation is often the result of defects in the miRNA biogenesis pathway, such as genomic mutation or aberrant expression/localization of enzymes and cofactors responsible of miRNA maturation. Alterations in the miRNA biogenesis machinery impact on the establishment and development of cancer programs. Accumulation of pri-microRNAs and corresponding depletion of mature microRNAs occurs in human cancers compared to normal tissues, strongly indicating an impairment of crucial steps in microRNA biogenesis. In agreement, inhibition of microRNA biogenesis, by depletion of Dicer1 and Drosha, tends to enhance tumorigenesis in vivo. The p53 tumor suppressor gene, TP53, is mutated in half of human tumors resulting in an oncogene with Gain-Of-Function activities. In this review we discuss recent studies that have underlined a role of mutant p53 (mutp53) on the global regulation of miRNA biogenesis in cancer. In particular we describe how a new transcriptionally independent function of mutant p53 in miRNA maturation, through a mechanism by which this oncogene is able to interfere with the Drosha processing machinery, generally inhibits miRNA processing in cancer and consequently impacts on carcinogenesis.

Citing Articles

Deregulation mechanisms and therapeutic opportunities of p53-responsive microRNAs in diffuse large B-cell lymphoma.

Voropaeva E, Orlov Y, Loginova A, Seregina O, Maksimov V, Pospelova T PeerJ. 2025; 13():e18661.

PMID: 39802185 PMC: 11720970. DOI: 10.7717/peerj.18661.


Post-Translational Modifications (PTMs) of mutp53 and Epigenetic Changes Induced by mutp53.

Benedetti R, Di Crosta M, DOrazi G, Cirone M Biology (Basel). 2024; 13(7).

PMID: 39056701 PMC: 11273943. DOI: 10.3390/biology13070508.


miRNA on the Battlefield of Cancer: Significance in Cancer Stem Cells, WNT Pathway, and Treatment.

Bhagtaney L, Dharmarajan A, Warrier S Cancers (Basel). 2024; 16(5).

PMID: 38473318 PMC: 10931375. DOI: 10.3390/cancers16050957.


Mechanisms of Regulation of the Expression of miRNAs and lncRNAs by Metformin in Ovarian Cancer.

Alfaro I, Vega M, Romero C, Garrido M Pharmaceuticals (Basel). 2023; 16(11).

PMID: 38004379 PMC: 10674581. DOI: 10.3390/ph16111515.


Expression profile of miRNAs computationally predicted to target PDL-1 in cervical tissues of different histology groups.

Leventakou D, Gouloumi A, Spathis A, Pouliakis A, Koufopoulos N, Pergialiotis V Front Cell Dev Biol. 2023; 11:1101041.

PMID: 36910137 PMC: 9998664. DOI: 10.3389/fcell.2023.1101041.


References
1.
Oren M . Decision making by p53: life, death and cancer. Cell Death Differ. 2003; 10(4):431-42. DOI: 10.1038/sj.cdd.4401183. View

2.
Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J . The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003; 425(6956):415-9. DOI: 10.1038/nature01957. View

3.
Calin G, Sevignani C, Dumitru C, Hyslop T, Noch E, Yendamuri S . Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004; 101(9):2999-3004. PMC: 365734. DOI: 10.1073/pnas.0307323101. View

4.
Zeng Y, Cullen B . Structural requirements for pre-microRNA binding and nuclear export by Exportin 5. Nucleic Acids Res. 2004; 32(16):4776-85. PMC: 519115. DOI: 10.1093/nar/gkh824. View

5.
Lee Y, Kim M, Han J, Yeom K, Lee S, Baek S . MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004; 23(20):4051-60. PMC: 524334. DOI: 10.1038/sj.emboj.7600385. View